
Fig. 3

Study 1: Mean apixaban plasma concentration-time profile (error bars show +1 standard deviation).




A= apixaban 2 x 5 mg Phase 3 tablets

B = apixaban 25 mL x 0.4 mg/mL liquid formulation

Fig. 4

Study 2: Mean apixaban plasma concentration-time profile (error bars show +1 standard deviation).




A= Single dose apixaban 5 mg (12.5 ml) liquid formulation administered by mouth via oral syringe

B = Single dose apixaban 5 mg (12.5 ml) liquid formulation administered via NGT immediately followed by 60 mL of D_5W via NGT

C = Single dose apixaban 5 mg (12.5 ml) liquid formulation administered via NGT immediately followed by 60 mL of infant formula via NGT

Fig. 5

Study 3: Mean apixaban plasma concentration-time profile (error bars show +1 standard deviation).



A = apixaban 5 mg liquid formulation administered orally (N=20)

B = apixaban 5 mg liquid formulation after Boost Plus® via NGT (N=20)

C = apixaban 5 mg crushed tablet administered via NGT (N=21)